Ampio Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company primarily engaged in the development of AmpionTM, its lead anti-inflammatory drug, which is currently undergoing clinical trials focused on the treatment of patients afflicted with COVID-19 induced acute respiratory distress syndrome (ARDS) as well as patients suffering from severe (KL-4) osteoarthritis of the knee (OAK). Both conditions impact a significant percentage of the population and due to the lack of any FDA approved drugs for treatment, there exists a significant unmet medical need. Ampion is backed by an extensive global patent portfolio with intellectual property protection extending through 2035. In addition, Ampion will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the biologics price competition and innovation act (BPCIA).
Company profile
Ticker
AMPE
Exchange
Website
CEO
Michael Macaluso
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Chay Enterprises, Inc.
SEC CIK
Corporate docs
IRS number
260179592
AMPE stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
13 Mar 23
8-K
Termination of a Material Definitive Agreement
7 Mar 23
8-K
Ampio Pharmaceuticals Issues Letter to Stockholders
17 Jan 23
8-K
Regulation FD Disclosure
27 Dec 22
8-K
Ampio Pharmaceuticals Announces NYSE American Removal of Trading Suspension
18 Nov 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Ampio Pharmaceuticals Announces Fifteen-to-One Reverse Stock Split
9 Nov 22
8-K
Ampio Pharmaceuticals Issues Letter to Stockholders
14 Oct 22
DEFA14A
Additional proxy soliciting materials
4 Oct 22
DEFA14A
Additional proxy soliciting materials
4 Oct 22
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 16.95 mm | 16.95 mm | 16.95 mm | 16.95 mm | 16.95 mm | 16.95 mm |
| Cash burn (monthly) | 1.98 mm | 14.25 k | 2.55 mm | 2.40 mm | 1.98 mm | 1.71 mm |
| Cash used (since last report) | 11.37 mm | 81.76 k | 14.65 mm | 13.79 mm | 11.37 mm | 9.82 mm |
| Cash remaining | 5.58 mm | 16.87 mm | 2.30 mm | 3.16 mm | 5.58 mm | 7.13 mm |
| Runway (months of cash) | 2.8 | 1183.5 | 0.9 | 1.3 | 2.8 | 4.2 |
Institutional ownership, Q4 2022
2.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 34 |
| Opened positions | 6 |
| Closed positions | 71 |
| Increased positions | 0 |
| Reduced positions | 26 |
| 13F shares | Current |
|---|---|
| Total value | 69.41 mm |
| Total shares | 6.47 mm |
| Total puts | 0.00 |
| Total calls | 763.66 k |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| CVI Investments | 5.60 mm | $2.21 mm |
| Terker Bruce E | 454.22 k | $0.00 |
| CVA Family Office | 73.57 k | $16.57 mm |
| Susquehanna International | 66.61 k | $15.00 mm |
| Millennium Management | 62.88 k | $14.00 k |
| Courier Capital | 38.33 k | $8.63 mm |
| Western Wealth Management | 24.85 k | $5.60 mm |
| Brighton Jones | 24.60 k | $5.54 mm |
| SNEX StoneX | 20.11 k | $5.00 k |
| UBS UBS Group AG - Registered Shares | 16.17 k | $3.72 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 Mar 22 | Elizabeth Varki Jobes | Stock Option Common Stock | Grant | Acquire A | No | No | 0.4513 | 150,000 | 67.70 k | 150,000 |
| 9 Feb 22 | Bar-Or David | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5295 | 75,000 | 39.71 k | 75,000 |
| 1 Jan 22 | Michael A Martino | Stock Option Common Stock | Grant | Acquire A | No | No | 0.57 | 250,000 | 142.50 k | 250,000 |
| 1 Jan 22 | Dan Stokely | Common Stock | Payment of exercise | Dispose F | No | No | 0.57 | 22,914 | 13.06 k | 312,274 |